<DOC>
	<DOCNO>NCT01337804</DOCNO>
	<brief_summary>This study compare bioequivalence omeprazole administer either Zegerid® powder oral suspension 20 mg Prilosec 40 mg capsule healthy participant .</brief_summary>
	<brief_title>A Study Compare Omeprazole Administered Zegerid® Powder Prilosec® Capsule Healthy Participants ( P08050 ) ( CL2010-12 )</brief_title>
	<detailed_description />
	<mesh_term>Heartburn</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Omeprazole , sodium bicarbonate drug combination</mesh_term>
	<criteria>Participant nonAsian origin . Female participant reproductive potential must negative pregnancy test agree use ( and/or partner use ) two acceptable method birth control begin screen visit , throughout study , 2 week last dose study drug . Participant Body Mass Index ( BMI ) ≤35 kg/m2 screen visit . Participant judge good health . Participant clinically significant abnormality electrocardiogram ( ECG ) . Participant nonsmoker and/or use nicotine nicotinecontaining product least 6 month . Participant mentally legally incapacitate , significant emotional problem time screen visit history clinically significant psychiatric disorder last 5 10 year . Participants situational depression may enrol study discretion investigator . Participant history illness , opinion study investigator , might confound result study pose additional risk participant participation study . Participant take gastric antisecretory drug ( e.g. , histamine receptor type2 antagonists [ H2RAs ] proton pump inhibitor [ PPIs ] ) , antacid , prescription thecounter ( OTC ) medication within 14 day prior Period 1 trial . Participant treat trial drug therapy , participate clinical trial 30 day prior Period 1 . Participant laboratory test result prior dose Period 1 deviate normal reference range establish local laboratory 20 % investigator judge possible clinical significance . Participant estimate creatinine clearance ≤80 mL/min base CockcroftGault equation . Participant history stroke , chronic seizure , major neurological disorder . Participant history clinically significant endocrine , gastrointestinal , cardiovascular , hematological , hepatic , immunological , renal , respiratory , genitourinary abnormality disease . Participants history uncomplicated kidney stone childhood asthma may enrol study discretion investigator . Participant history neoplastic disease . Participant nursing mother . Participant history serologic evidence hepatitis B C abnormal liver function test ( except benign , selflimited hepatitis A &gt; 5 year prior randomization ) , hepatic biliary tract disease , history gastrointestinal tract surgery . Participant allergy hypersensitivity component/excipient study drug , history significant multiple and/or severe allergy ( include latex allergy ) , anaphylactic reaction significant intolerability prescription nonprescription drug food . Participant unable refrain anticipates use medication , include prescription nonprescription drug herbal remedy ( St. John 's Wort [ hypericum perforatum ] ) begin approximately 2 week ( 5 halflives ) prior administration initial dose study drug , throughout study ( include washout interval treatment period ) , telephone followup . There may certain medication permit . Participants must explicitly warn potential risk take erythromycin , clarithromycin , nefazodone , ketoconazole , itraconazole , cyclosporine , human immunodeficiency virus ( HIV ) protease inhibitor study . Participant consume excessive amount alcohol , define great 3 glass per day alcoholic beverage ( 1 glass approximately equivalent : 10 ounce beer , 4 ounce wine , 1 ounce distil spirit ) . Participant consume grapefruit juice , grapefruits grapefruit product within 2 week prior administration initial dose study drug , agree refrain consumption throughout study ( include washout interval treatment period ) telephone followup . Participant consume excessive amount , define great 6 serving ( 1 serve approximately equivalent 120 mg caffeine ) coffee , tea , cola , chocolate , caffeinated beverage per day . Participant major surgery , donate lose 1 unit blood ( approximately 500 mL ) participate another investigational study within 30 day prior Period 1 . The 4week window derive date last study procedure ( i.e. , telephone followup ) previous study screen visit current study . Participant currently regular user ( include `` recreational use '' ) illicit drug history drug ( include alcohol ) abuse within approximately 1 year . There concern investigator regard safe participation participant study reason ; investigator considers participant inappropriate participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>